SEARCH

SEARCH BY CITATION

References

  • 1
    Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 2
    Talley NJ. Pharmacologic therapy for irritable bowel syndrome. Am J Gastroenterol 2003;98: 7508.
    Direct Link:
  • 3
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123: 210831.
  • 4
    Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome. an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003;17: 64350.
  • 5
    Hahn BA, Yan S, Strassel S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999;60: 7781.
  • 6
    Olden KW. Approach to the patient with severe refractory irritable bowel syndrome. Curr Treat Options Gastroenterol 2003;6: 31117.
  • 7
    Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001;19: 64353.
  • 8
    Kellow JE. Treatment goals in irritable bowel syndrome. Int J Clin Pract 2001;55: 54651.
  • 9
    Thompson WG, Hungin AP, Neri M, et al. The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Eur J Gastroenterol Hepatol 2001;13: 9339.
  • 10
    Borum ML. Irritable bowel syndrome. Gastroenterology 2001;28: 52338.
  • 11
    Zaman A. Irritable bowel syndrome. Clin Cornerstone 2002;4: 2232.
  • 12
    Drossman DA, Whitehead WE, Camilleri M, for the Patient Care Committee American Gastroenterology Association. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997;112: 212037.
  • 13
    Camilleri M. Management of irritable bowel syndrome. Gastroenterology 2001;120: 65268.
  • 14
    Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56: 3629.
  • 15
    Fennerty MB. Traditional therapies for irritable bowel syndrome: an evidence-based appraisal. Rev Gastroenterol Disord 2003;3(Suppl. 2):S1824.
  • 16
    Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133: 13647.
  • 17
    Kind P. The EuroQol instrument. an index of health-related quality of life. In: SpilkerB, ed., Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia, PA: Lippincott-Raven Publishers, 1996.
  • 18
    Brooks R. EuroQol: the current state of play. Health Policy 1996;37: 5372.
  • 19
    The EuroQoL database. Available from: http://www.euroqol.org. [Accessed October 5, 2005].
  • 20
    Weinstein MC, Siegel JE, Gold MR, et al. Recommendation of the panel on cost-effectiveness in health and medicine. JAMA 1996;276: 12538.
  • 21
    Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002;20: 45562.
  • 22
    Drossman DA, Richter JE, Talley NJ, eds. et al. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment (1st ed.). McLean, VA: Degnon Associates, 1994.
  • 23
    Ricci JF, Walters S, Ward S, Akehurst R. Quality of life of IBS patients in the United Kingdom compared with a general population sample. Gastroenterology 2003;123: A518.
  • 24
    Badia X, Mearin F, Caballero A, et al. Economic burden of irritable bowel syndrome (IBS): one year results. RITMO study. Value Health 2003; 6: 684.
  • 25
    Drossman DA, ed. Rome II: The Functional Gastrointestinal Disorders—Diagnosis, Pathophysiology, and Treatment: a Multinational Consensus (2nd ed.). McLean, VA: Degnon Associates, 2000.
  • 26
    Grüger J, Schultes HJ, Pirk O, Van Assche D. The utility benefits of tegaserod in irritable bowel syndrome. Gut 2001;49(Suppl. III):A3001.
  • 27
    Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. In: BrooksR, RabinR, De CharroF, eds., The Measurement and Valuation of Health States Using EQ-5D: A European Perspective. Dordrecht: Kluwer Academic Publishers, 2003; 2941.
  • 28
    Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33: 33743.
  • 29
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
  • 30
    Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43: 40011.
  • 31
    Drossman DA, Patrick DL, Whitehead WE, et al. Further Validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95: 9991007.
    Direct Link:
  • 32
    SPSS , Inc. Statistical Package for the Social Sciences Base 10.0 User's Guide. Chicago, IL: SPSS, Inc., 1999.
  • 33
    Cohen J. Statistical Power Analysis for the Behavioral Sciences (Revised Edition). New York: Academic Press, 1997.
  • 34
    Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Chichester: John Wiley & Sons, 2000.
  • 35
    Granlek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119: 65460.
  • 36
    Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQoL: Results from UK General Population Survey. CHE Discussion Paper 138. York: Centre for Health Economics, University of York (UK), 1997.